Current Landscape of Adoptive Cell Therapy and Challenge to Develop “Off-The-Shelf” Therapy for Hepatocellular Carcinoma.
Journal of gastroenterology and hepatology 40(4), 791-807, 2025年4月, 10.1111/jgh.16872 [39865534]
Development of chimeric antigen receptor T cells targeting cancer-expressing podocalyxin.
Regenerative therapy 28, 292-300, 2025年3月, 10.1016/j.reth.2024.12.010 [39867135]
Human iPSC-derived CD4+ Treg-like cells engineered with chimeric antigen receptors control GvHD in a xenograft model.
Cell stem cell 31(6), 795-802, 2024年6月6日, 10.1016/j.stem.2024.05.004 [38848686]
A culture method with berbamine, a plant alkaloid, enhances CAR-T cell efficacy through modulating cellular metabolism.
Communications biology 7(1), 685-685, 2024年6月4日, 10.1038/s42003-024-06297-0 [38834758]
Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy.
Inflammation and regeneration 44(1), 20-20, 2024年4月18日, 10.1186/s41232-024-00328-3 [38637837]
Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma.
Blood 143(10), 895-911, 2024年3月7日, 10.1182/blood.2023020528 [37890146]
Effective and stable gene transduction in rhesus macaque iPSCs capable of T-lineage differentiation utilizing the piggyBac system.
Regenerative therapy 27, 104-111, 2024年3月, 10.1016/j.reth.2024.03.002 [38545443]
Lineage tracing of T cell differentiation from T-iPSC by 2D feeder-free culture and 3D organoid culture.
Frontiers in immunology 14, 1303713-1303713, 2023年12月15日, 10.3389/fimmu.2023.1303713 [38162650]
Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity
Mini-TCRs: Truncated T cell receptors to generate T cells from induced pluripotent stem cells
Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells.
Biochemical and biophysical research communications 662, 76-83, 2023年4月20日, 10.1016/j.bbrc.2023.04.067 [37099813]
Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells.
Nature biomedical engineering 7(1), 24-37, 2023年1月, 10.1038/s41551-022-00969-0 [36509913]
Improved anti-solid tumor response by humanized anti-podoplanin chimeric antigen receptor transduced human cytotoxic T cells in an animal model.
Genes to cells : devoted to molecular & cellular mechanisms 27(9), 549-558, 2022年7月5日, 10.1111/gtc.12972 [35790497]
Sustainable Antiviral Efficacy of Rejuvenated HIV-Specific Cytotoxic T Lymphocytes Generated from Induced Pluripotent Stem Cells.
Journal of virology 96(6), e0221721-, 2022年3月23日, 10.1128/jvi.02217-21 [35107374]
The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-1derived iPS cells
Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors
International Journal of Hematology 114(5), 572-579, 2021年11月1日, 10.1007/s12185-020-02951-5 [32705572]
Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy.
Molecular therapy : the journal of the American Society of Gene Therapy 29(10), 3027-3041, 2021年10月6日, 10.1016/j.ymthe.2021.05.016 [34023508]
Generation of macrophages with altered viral sensitivity from genome-edited rhesus macaque iPSCs to model human disease.
Molecular therapy. Methods & clinical development 21, 262-273, 2021年6月11日, 10.1016/j.omtm.2021.03.008 [33869654]
Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy.
Molecular therapy. Methods & clinical development 21, 171-179, 2021年6月11日, 10.1016/j.omtm.2021.03.002 [33816647]

